Discovery of a restriction factor for hepatitis B virus

April 08, 2019

Hepatitis B is a viral liver infection that can lead to acute or chronic conditions. Although there is a vaccine that offers protection against the virus, current treatments which prevent the virus from replicating are not curative for infected individuals. Scientists at the Institut Pasteur working in collaboration with the CNRS have demonstrated that a cellular protein is capable of acting as a restriction factor for the hepatitis B virus by degrading the viral DNA.

Chronic infection with hepatitis B virus (HBV) affects more than 250 million people worldwide, putting them at high risk of developing serious liver conditions including liver cancer, an extremely severe form of cancer for which scientists have not yet found an effective treatment.

Although several antiviral treatments can effectively inhibit HBV replication, they are not curative and do not fully eliminate the virus. It is therefore important to eliminate the virus in chronic carriers so as to prevent the disease from developing into cancer.

When viruses infect cells, they make use of cellular machinery, in other words the cell's built-in multiplication mechanisms. To combat viruses, some cellular proteins are capable of interfering with these mechanisms. These are known as viral restriction factors.

Scientists at the Institut Pasteur postulated that a protein mainly produced in several organs, including the liver, could take on the role of a restriction factor.

"During our research, we demonstrated that a cellular protein capable of degrading DNA could be incorporated into the viral particle and induce degradation of the hepatitis B virus genome," explains Jean-Pierre Vartanian from the Institut Pasteur's Molecular Retrovirology Unit. In this process, the enzyme, known as DNase I, produces empty virus particles.

DNase I, considered as a new antiviral restriction factor, is expressed in vitro in a hypoxic (oxygen-depleted) environment and also in patients infected with hepatitis B virus.

"The aim of our research is to use this protein to produce viral particles containing the nuclease so that we can pursue a "Trojan horse" approach," continues Jean-Pierre Vartanian. These particles will target infected liver cells, inducing degradation of the viral and cellular DNA found in them.
-end-


Institut Pasteur

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.